Cooke & Bieler LP Decreases Stock Holdings in Becton, Dickinson and Company $BDX

Cooke & Bieler LP lessened its holdings in Becton, Dickinson and Company (NYSE:BDX) by 5.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 885,798 shares of the medical instruments supplier’s stock after selling 54,084 shares during the period. Becton, Dickinson and Company comprises approximately 1.7% of Cooke & Bieler LP’s holdings, making the stock its 14th biggest holding. Cooke & Bieler LP owned about 0.31% of Becton, Dickinson and Company worth $165,795,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in BDX. SOA Wealth Advisors LLC. boosted its position in shares of Becton, Dickinson and Company by 256.8% in the third quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 95 shares during the period. Bell Investment Advisors Inc lifted its position in Becton, Dickinson and Company by 474.1% during the 2nd quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 128 shares in the last quarter. Grey Fox Wealth Advisors LLC purchased a new position in Becton, Dickinson and Company in the 3rd quarter worth approximately $32,000. Bank of Jackson Hole Trust grew its position in Becton, Dickinson and Company by 85.6% in the second quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock valued at $35,000 after acquiring an additional 95 shares in the last quarter. Finally, CVA Family Office LLC raised its stake in shares of Becton, Dickinson and Company by 79.5% during the second quarter. CVA Family Office LLC now owns 219 shares of the medical instruments supplier’s stock valued at $38,000 after purchasing an additional 97 shares during the period. 86.97% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 217 shares of the firm’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the sale, the director directly owned 35,816 shares in the company, valued at approximately $6,324,389.28. This trade represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Michael David Garrison sold 1,610 shares of the stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the sale, the executive vice president directly owned 12,095 shares in the company, valued at approximately $2,509,228.70. This trade represents a 11.75% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 2,605 shares of company stock valued at $524,643. 0.40% of the stock is owned by company insiders.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock opened at $201.84 on Monday. The company has a market cap of $57.51 billion, a PE ratio of 34.62, a P/E/G ratio of 2.23 and a beta of 0.23. The company has a fifty day moving average price of $197.40 and a two-hundred day moving average price of $190.53. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.11 and a quick ratio of 0.64. Becton, Dickinson and Company has a 12 month low of $162.29 and a 12 month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share for the quarter, topping analysts’ consensus estimates of $3.92 by $0.04. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The company had revenue of $5.89 billion for the quarter, compared to analysts’ expectations of $5.91 billion. During the same period in the prior year, the company earned $3.81 earnings per share. The firm’s revenue was up 8.3% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. Research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, December 31st. Investors of record on Monday, December 8th were given a dividend of $1.05 per share. The ex-dividend date was Monday, December 8th. This represents a $4.20 dividend on an annualized basis and a yield of 2.1%. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s payout ratio is presently 72.04%.

Wall Street Analyst Weigh In

BDX has been the topic of several analyst reports. Wall Street Zen downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Piper Sandler cut their price target on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research note on Friday, November 7th. Jefferies Financial Group upped their target price on Becton, Dickinson and Company from $215.00 to $220.00 and gave the company a “buy” rating in a research report on Wednesday, December 10th. Finally, Bank of America increased their target price on Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a research note on Monday, January 5th. Four equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $207.64.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.